Search
Now showing items 1-4 of 4
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
(ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)
Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ...
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-08-15)
In breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte subsets, immunoglobulin expression, and clonal features in breast ...
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
(CELL PRESS, 2021-12-21)
Despite its role in cancer surveillance, adoptive immunotherapy using γδ T cells has achieved limited efficacy. To enhance trafficking to bone marrow, circulating Vγ9Vδ2 T cells are expanded in serum-free medium containing ...
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
(MASSACHUSETTS MEDICAL SOC, 2021-06-24)
BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with ...